As­traZeneca looks to re­bound from pro­duc­tion de­lays for its Covid-19 vac­cine with new fill-fin­ish deal

The re­la­tion­ship be­tween As­traZeneca and the EU has been on edge in re­cent weeks af­ter pro­duc­tion de­lays have scut­tled roll­out plans for the British drug­mak­er’s Covid-19 vac­cine. Now, look­ing to squash wor­ries its pro­duc­tion can’t keep up with de­mand, As­traZeneca is bring­ing on a new part­ner it hopes can right the ship.

As­traZeneca has tapped Ger­many’s IDT Bi­ologi­ka to ramp up im­me­di­ate pro­duc­tion of its ade­n­ovirus-based Covid-19 vac­cine, dubbed “Covid-19 Vac­cine As­traZeneca,” and build long-term ca­pac­i­ty to han­dle fill-fin­ish work for the shot, the British drug­mak­er said Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER